Centile Bioscience Inc. — SEC Form D Filing

Centile Bioscience Inc. filed an SEC Form D on April 16, 2026, reporting $3.05M raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
April 16, 2026
Amount reported
$3.05M
Round stage
Seed
Industry
Healthcare Technology
Website
https://centilebio.com/

What the company does

Securities: Equity, Convertible securities. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Clinicians face challenges in effectively utilizing the vast amount of data from brain imaging scans, which often remain unexamined, leading to poorer patient outcomes.

Solution

Centile Bioscience uses data science and algorithmic intelligence to analyze brain scans and develop actionable insights, enhancing diagnostic accuracy and patient care.

Why now

The demand for effective brain disease diagnostics is escalating due to an aging population and a declining workforce of radiologists.

Verdict

Investors said yes because Centile Bioscience presented a clear solution to the challenge of underutilized brain imaging data, not because competitors were absent. They were betting on the urgent demand for enhanced diagnostic capabilities amid a shrinking number of qualified radiologists, which implies a potential market shift towards automated solutions. However, the limited upside stems from the still-maturing nature of AI in diagnostics, which may constrain durability and widespread adoption.

Source: SEC EDGAR Form D filing